DEF 14A: Vivani Medical, Inc. Announces 2024 Annual Meeting of Stockholders

Vivani Medical, Inc. is set to hold its 2024 Annual Meeting of Stockholders virtually on June 27, 2024, to vote on the election of directors, ratification of the independent auditor, and executive compensation.

Summary

• Vivani Medical, Inc. will hold its 2024 Annual Meeting of Stockholders on June 27, 2024, at 10:00 a.m. Pacific Time, as a virtual meeting.
• Stockholders will vote on three proposals: electing six directors, ratifying the appointment of BPM LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and approving, on a non-binding advisory basis, the compensation of the company's named executive officers.
• The board of directors recommends voting FOR all three proposals.
• The record date for determining stockholders eligible to vote at the Annual Meeting was April 29, 2024.
• As of the record date, there were 54,978,465 shares of common stock outstanding and entitled to vote.
• The proxy statement and the 2023 Annual Report are available at www.proxydocs.com/VANI and on the Investors section of the company's website at www.vivani.com.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The company is recommending voting FOR all proposals, which suggests a positive outlook from management's perspective.

Positives

• The company is providing stockholders with multiple ways to vote, including online, by phone, and by mail.
• The board is actively engaged in risk oversight, with specific committees assigned to oversee various risk areas.
• The company has a Compensation Recovery Policy in place, allowing for the recovery of incentive-based compensation from executive officers in the event of an accounting restatement.
• The company has adopted a Code of Business Conduct and Ethics applicable to its principal executive officer, employees, officers, directors, agents and representatives.

Risks

• The proxy statement notes that certain directors had interests in the merger with Nano Precision Medical, Inc. (NPM) that were different from the interests of Second Sight's stockholders generally, which could have presented conflicts of interest.
• The company's success depends on attracting and retaining qualified personnel, including executive officers and directors.

Future Outlook

The company is soliciting proxies for the 2024 Annual Meeting and any postponement or adjournment thereof.

Management Comments

• Adam Mendelsohn, Chief Executive Officer, invites stockholders to attend the Annual Meeting and emphasizes the importance of their vote.

Industry Context

This is a standard proxy statement for a publicly traded company, outlining the matters to be voted on at the annual meeting and providing information about the company's governance, executive compensation, and related matters.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity awards, is typical for publicly traded companies of similar size and stage in the biotechnology industry.
• The use of a compensation consultant (Compensia, LLC) to assess director, executive, and employee compensation is a common practice among publicly traded companies to ensure that compensation is aligned with market levels and performance.
• The company's commitment to board diversity and its compliance with Nasdaq Rule 5605 are consistent with industry trends and regulatory requirements.
• The establishment of an Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, each with independent directors, is a standard practice for publicly traded companies to ensure proper oversight and governance.

Related Party Transactions

• The proxy statement discloses certain relationships and related transactions, including the merger with Nano Precision Medical, Inc. (NPM) and a SAFE agreement between Second Sight and NPM.
• Certain directors had interests in the merger that were different from the interests of Second Sight's stockholders generally, which could have presented conflicts of interest.

Stakeholder Impact

• The proposals being voted on at the Annual Meeting will impact stockholders, as they relate to the election of directors, the selection of the independent auditor, and executive compensation.
• The company's performance and governance practices will impact employees, customers, and other stakeholders.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold the Annual Meeting on June 27, 2024, to conduct the business outlined in the proxy statement.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Election of Directors, Audit Committee, BPM LLP, Vivani Medical, Governance